Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback